• 简

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Henry Schein (HSIC) Stock Rises On Margin Gains And Higher Guidance

    Simply Wall St·08/05/2026 02:54:39
    语音播报

    Henry Schein stock closed up 3.0% at US$89.11, which indicates that the market responded positively. The headline is simple: this was a margin story. Non GAAP operating margin reached 7.21% and adjusted EBITDA came in at US$288 million, which gave investors confidence that the profit engine in this healthcare distributor is still working.

    Short term traders are reacting to the beat and the raised non GAAP earnings guidance. Longer term holders will focus on whether this early lift in profitability can be sustained given the company’s high debt load and still modest 3% net margin.

    Is Henry Schein at US$89.11 a genuine DCF bargain or just expensive on earnings versus peers? Compare the implied upside and key assumptions side by side using the valuation analysis for Henry Schein

    Q2 2026 Earnings Summary

    • Revenue (Q2 2026 vs. Q2 2025): US$3,458 million vs. US$3,240 million (up about 6.7%)
    • Net Income, Excluding Extra Items (Q2 2026 vs. Q2 2025): US$94 million vs. US$86 million (up about 9.3%)
    • Basic EPS (Q2 2026 vs. Q2 2025): US$0.83 vs. US$0.71 (up about 17.5%)
    • Non GAAP Operating Margin (Q2 2026 vs. Q2 2025): 7.21% vs. 6.96% (improved by about 25 basis points)

    Prefer a clear visual story instead of scrolling through dense tables and earnings PDFs for Henry Schein? See the full picture of the stock, including a concise view of its valuation, in the company report for Henry Schein.

    NasdaqGS:HSIC Trailing 12-Month Revenue & Expenses Breakdown as at Aug 2026
    NasdaqGS:HSIC Trailing 12-Month Revenue & Expenses Breakdown as at Aug 2026

    Henry Schein bull case tests margin and mix story

    The bullish view says Henry Schein can use higher margin segments and cost savings to build a stronger profit engine. Q2 results give that claim some support. Non GAAP operating margin reached 7.21% and improved by about 25 basis points year on year. Non GAAP operating income grew faster than sales and adjusted EBITDA rose 12.7%. That lines up with the value creation plan that targets at least US$200m of operating income uplift and a US$125m run rate by the end of 2026. Higher growth in Specialty Products, Home Solutions and the Global Technology Group, which has about 90% recurring revenue, also fits the mix shift narrative. The raised full year non GAAP EPS and sales guidance suggests management sees enough traction in these programs to commit to higher profit and revenue targets.

    Henry Schein bear case focuses on growth and leverage

    The bear case argues that Henry Schein faces sluggish organic growth, margin pressure and execution risk around restructuring and leverage. Q2 revenue grew 6.7%, with internal sales up 4.6%, which is better than the modest growth worries but still not a high growth profile for a distributor leaning on cost programs. Distribution margins remain exposed to pricing in categories like gloves and to procurement pressure from larger dental groups. The net margin is still about 3%, which keeps the balance sheet in focus given the high debt load flagged earlier in the article. Execution risk also remains. The company is reshaping leadership, consolidating global supply chain operations and leaning on KKR backed value creation efforts. Any delay against the US$125m 2026 profit lift target would quickly reopen questions about how much of today’s margin progress is repeatable.

    Reveal where the surface looks calm, but the multi year models for Henry Schein start to diverge from today's US$89.11 price. See where the consensus might quietly be bracing for the next inflection point with the analyst estimates for Henry Schein.

    Stay Ahead With Simply Wall St

    If Henry Schein's margin story and raised guidance have caught your attention, register for free with Simply Wall St and add it to a Watchlist so you can track the share price against fair value and wait for a setup that fits your plan. After you have taken a position, keep your focus with the Portfolio Command Center that highlights key updates on your holdings and filters out day to day noise. For a broader view on what other investors are seeing in Henry Schein and similar stocks, tap into the Community to compare viewpoints and refine your thesis. By spotting potential catalysts and risks early, you give yourself a better chance to react quickly and stay ahead of the market.

    Seeking Alternatives Beyond Henry Schein?

    Fresh stock ideas can move quickly, and the best setups often fly under the radar for now. Check these curated lists before the window narrows and get in early.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.